Anabolism Versus Antiresorption: A Quadruple Labeling Histomorphometry Study to Compare the Mechanism of Action of Teriparatide and Denosumab in Postmenopausal Women With Osteoporosis

Trial Profile

Anabolism Versus Antiresorption: A Quadruple Labeling Histomorphometry Study to Compare the Mechanism of Action of Teriparatide and Denosumab in Postmenopausal Women With Osteoporosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2016

At a glance

  • Drugs Teriparatide (Primary) ; Calcium; Demeclocycline; Denosumab; Tetracycline; Vitamin D
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms AVA
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Feb 2016 Primary endpoint has been met. (Change From Baseline to 3 Months in Mineralizing Surface (MS) /Bone Surface (BS) in the Cancellous Compartment (CC) of the Iliac Crest Bone Biopsies), as per an abstract published in the Journal of Clinical Endocrinology and Metabolism.
    • 09 Feb 2016 Results published in the Journal of Clinical Endocrinology and Metabolism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top